Evidence map›Paper›PMID 18650261›Full record

ArticleAmerican journal of physiology. Cell physiology2008

A GSK-3/TSC2/mTOR pathway regulates glucose uptake and GLUT1 glucose transporter expression.

Carolyn L Buller, Robert D Loberg, Ming-Hui Fan, Qihong Zhu, James L Park, Eileen Vesely, Ken Inoki, Kun-Liang Guan, Frank C Brosius

Open access · greenAbstract read
In one paragraph

Article in American journal of physiology. Cell physiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
128citing papers in PubMed, 1 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

128 citing papers in PubMed, 1 synthesis or guideline pooled it, 229 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Insulin and cancer: a tangled web.The Biochemical journal · 2022
    Review
  20. Review

68 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Carolyn L BullerDepartment of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109-0680, USA.
Robert D Loberg
Ming-Hui Fan
Qihong Zhu
James L Park
Eileen Vesely
Ken Inoki
Kun-Liang Guan
Frank C Brosius
University of Michigan–Ann Arbor · US

Funding

SYTEMS AND INTEGRATIVE BIOLOGYT32GM008322 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI LOW, MALCOLM JAMES · 1990 to 2020
$5.7M
Vascular smooth muscle glucose transport in hypertensionR01HL065567 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROSIUS, FRANK C · 2001 to 2011
$2.7M
Lysosomal cholesterol-dependent anabolic regulationR01DK124709 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI INOKI, KEN · 2022 to 2025
$2.1M
Vascular smooth muscle apoptosis prevention by glucoseR01HL060156 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BROSIUS, FRANK C · 1998 to 2005
$1.5M
NHLBI NIH HHS HL-65567NHLBI NIH HHS R01 HL065567NHLBI NIH HHS R01-HL-60156NIDDK NIH HHS R01 DK124709NIGMS NIH HHS T32 GM008322
6 · The paper itself

Abstract

Glucose transport is a highly regulated process and is dependent on a variety of signaling events. Glycogen synthase kinase-3 (GSK-3) has been implicated in various aspects of the regulation of glucose transport, but the mechanisms by which GSK-3 activity affects glucose uptake have not been well defined. We report that basal glycogen synthase kinase-3 (GSK-3) activity regulates glucose transport in several cell types. Chronic inhibition of basal GSK-3 activity (8-24 h) in several cell types, including vascular smooth muscle cells, resulted in an approximately twofold increase in glucose uptake due to a similar increase in protein expression of the facilitative glucose transporter 1 (GLUT1). Conversely, expression of a constitutively active form of GSK-3beta resulted in at least a twofold decrease in GLUT1 expression and glucose uptake. Since GSK-3 can inhibit mammalian target of rapamycin (mTOR) signaling via phosphorylation of the tuberous sclerosis complex subunit 2 (TSC2) tumor suppressor, we investigated whether chronic GSK-3 effects on glucose uptake and GLUT1 expression depended on TSC2 phosphorylation and TSC inhibition of mTOR. We found that absence of functional TSC2 resulted in a 1.5-to 3-fold increase in glucose uptake and GLUT1 expression in multiple cell types. These increases in glucose uptake and GLUT1 levels were prevented by inhibition of mTOR with rapamycin. GSK-3 inhibition had no effect on glucose uptake or GLUT1 expression in TSC2 mutant cells, indicating that GSK-3 effects on GLUT1 and glucose uptake were mediated by a TSC2/mTOR-dependent pathway. The effect of GSK-3 inhibition on GLUT1 expression and glucose uptake was restored in TSC2 mutant cells by transfection of a wild-type TSC2 vector, but not by a TSC2 construct with mutated GSK-3 phosphorylation sites. Thus, TSC2 and rapamycin-sensitive mTOR function downstream of GSK-3 to modulate effects of GSK-3 on glucose uptake and GLUT1 expression. GSK-3 therefore suppresses glucose uptake via TSC2 and mTOR and may serve to match energy substrate utilization to cellular growth.

Indexed as

Signal TransductionAnimalsCell LineGlucoseGlucose Transporter Type 1Glycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaIndolesMaleimidesMutationPhosphorylationProtein Kinase InhibitorsProtein KinasesRatsRibosomal Protein S6 Kinases, 70-kDaRNA, MessengerGlucoseGlucose Transporter Type 1Glycogen Synthase Kinase 3Glycogen Synthase Kinase 3 betaGsk3b protein, ratIndolesMaleimidesmTOR protein, ratProtein Kinase InhibitorsProtein KinasesRibosomal Protein S6 Kinases, 70-kDaRNA, MessengerSB 216763SirolimusSlc2a1 protein, ratTOR Serine-Threonine KinasesTsc2 protein, ratTuberous Sclerosis Complex 2 ProteinTumor Suppressor Proteins

Identifiers

PMID18650261
PMCPMC2544442
OpenAlexW2058221507

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.